Heresco-Levy U, Javitt DC, Ermilov M, et al. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
Arch Gen Psychiatry.
1999;56:29 - 36.
Heresco-Levy U, Javitt DC, Ermilov M, et al. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
Br J Psychiatry.
1996;169:610 - 617.
Javitt DC, Zylberman I, Zukin SR, et al. Amelioration of negative symptoms in schizophrenia by glycine.
Am J Psychiatry.
1994;151:1234 - 1236.
Semba J. Glycine therapy of schizophrenia; its rationale and a review of clinical trials [translated from Japanese].
Nihon Shinkei Seishin Yakurigaku Zasshi.
1998;18:71 - 80.
Potkin SG, Jin Y, Bunney BG, et al. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia.
Am J Psychiatry.
1999;156:145 - 147.
Evins AE, Fitzgerald SM, Wine L, et al. Placebo-controlled trial of glycine added to clozapine in schizophrenia.
Am J Psychiatry.
2000;157:826 - 828.
Liu P, Luo H, Shen Y, et al. Combined use
of Ginkgo biloba
extracts on the efficacy and adverse reactions of various antipsychotics [translated from Chinese].
Chin J Clin Pharmacol.
1997;13:193 - 198.
Zhang XY, Zhou DF, Zhang PY, et al. A double-blind, placebo-controlled trial of extract of
Ginkgo biloba
added to haloperidol in treatment-resistant patients with schizophrenia.
J Clin Psychiatry.
2001;62:878 - 883.
Tsai G, Yang P, Chung LC, et al. D-serine added to antipsychotics for the treatment of schizophrenia.
Biol Psychiatry.
1998;44:1081 - 1089.
Peet M, Brind J, Ramchand CN, et al. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia.
Schizophr Res.
2001;49:243 - 251.
Fenton WS, Dickerson F, Boronow J, et al. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia.
Am J Psychiatry.
2001;158:2071 - 2074.
Emsley R, Myburgh C, Oosthuizen P, et al. Randomized, placebo-controlled study of ethyl-eicosapentaenoic Acid as supplemental treatment in schizophrenia.
Am J Psychiatry.
2002;159:1596 - 1598.
Folkers K. Basic chemical research on coenzyme Q
10
and integrated clinical research on therapy of diseases. In Lenaz G, ed.
Coenzyme Q.
New York: John Wiley and Sons; 1985.
Kishi T, Makino K, Okamoto T, et al. Inhibition of myocardial respiration by psychotherapeutic drugs and prevention by coenzyme Q. In: Folkers K, Yamagami T, Littarru GP, eds. International Symposium on Coenzyme Q.
Biomedical and clinical aspects of coenzyme Q.
Vol 2. New York, NY: Elsevier Science Publishing Co.; 1980:139 - 157.
Palasciano G, et al. The effect of silymarin on plasma levels of malondialdehyde in patients receiving long term treatment with psychotropic drugs.
Curr Ther Res.
1994;55:537 - 545.
Hoffman RE, Boutros NN, Hu S, et al. Transcranial magnetic stimulation and auditory hallucinations in schizophrenia.
Lancet.
2000;355:1073 - 1075.
Rollnik JD, Huber TJ, Mogk H, et al. High frequency repetitive transcranial magnetic stimulation (rTMS) of the dorsolateral prefrontal cortex in schizophrenic patients.
Neuroreport.
2000;11:4013 - 4015.
Shamir E, Laudon M, Barak Y, et al. Melatonin improves sleep quality of patients with chronic schizophrenia.
J Clin Psychiatry.
2000;61:373 - 377.
Hawkins DR, Bortin AW, Runyon RP. Orthomolecular psychiatry: niacin and megavitamin therapy.
Psychosomatics.
1970;11:517 - 21.
Hoffer A. Megavitamin B-3 therapy for schizophrenia.
Can Psychiatr Assoc J.
1971;16:499 - 504.
Newbold HL, Mosher LR. Niacin and the schizophrenic patient.
Am J Psychiatry.
1970;127:535 - 536.
Petrie WM, Ban TA, Ananth JV. The use of nicotinic acid and pyridoxine in the treatment of schizophrenia.
Int Pharmacopsychiatry.
1981;16:245 - 250.
Petrie WM, Ban TA. Vitamins in psychiatry. Do they have a role?
Drugs.
1985;30:58 - 65.
Procter A. Enhancement of recovery from psychiatric illness by methylfolate.
Br J Psychiatry.
1991;159:271 - 272.
Vaughan K, McConaghy N. Megavitamin and dietary treatment in schizophrenia: a randomised, controlled trial.
Aust N Z J Psychiatry.
1999;33:84 - 88.
Wittenborn JR, Weber ES, Brown M. Niacin in the long-term treatment of schizophrenia.
Arch Gen Psychiatry.
1973;28:308 - 315.
Richardson MA.
Amino acids in psychiatric disease.
Washington, DC: American Psychiatric Press; 1990.
Mosnik DM, Spring B, Rogers K, et al. Tardive dyskinesia exacerbated after ingestion of phenylalanine by schizophrenic patients.
Neuropsychopharmacology.
1997;16:136 - 146.
Schelosky L, et al. Kava and dopamine antagonism.
J Neurol Neurosurg Psych.
1995;58:639 - 640.
Attenburrow MJ, Odontiadis J, Murray BJ, et al. Chromium treatment decreases the sensitivity of 5-HT(2A) receptors.
Psychopharmacology.
2002;159:432 - 436.
Reading SA. Chromium picolinate.
J Fla Med Assoc.
1996;83:29 - 31.
Brinker F.
Herb contraindications and drug interactions.
2nd ed. Sandy, OR: Eclectic Medical Publications; 1998:140 - 141.
Strous RD, Maayan R, Lapidus R, et al. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia.
Arch Gen Psychiatry. 2003;60:133 - 141.
La información aquí suministrada complementa la atención recibida por su médico. De ninguna forma intenta sustituir el consejo de un professional medico. LLAME A SU MEDICO DE INMEDIATO SI PIENSA QUE PODRIA TENER UNA EMERGENCIA. Siempre busque consejo médico antes de comenzar un nuevo tratamiento o si tiene preguntas sobre una condición médica.